Image Place holder

Dae Won Kim, MD


Specialty: Medical Oncology
Program: Gastrointestinal Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Dr. Kim received his MD degree from the Inha University School of Medicine, Incheon, South Korea. He then completed an Internal Medicine Residency at St. Luke’s Roosevelt Hospital Center, New York City (NY) and a Melanoma Immunotherapy Fellowship at MD Anderson Cancer Center, Houston, Texas. He recently completed a Medical Oncology Fellowship at the Moffitt Cancer Center and the University of South Florida. Dr. Kim will specialize in the treatment of gastrointestinal cancers, with a focus on immunotherapy.

Education & Training

Board Certification:

  • Internal Medicine

Fellowship:

  • MD Anderson Cancer Center - Melanoma Immunotherapy
  • H. Lee Moffitt Cancer Center and Research Institute - Medical Oncology

Residency:

  • St. Luke's Roosevelt Hospital Center - Internal Medicine

Medical School:

  • Inha University School of Medicine, Korea - MD
Participating Trials

CLINICAL TRIAL 17932
A Phase 1a/1b Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular Cancer
Condition: Gastrointestinal Tumor
Intervention: BAY 43-9006 (Sorafenib); GSK1120212 (Trametinib); Sorafenib; Trametinib
Open

CLINICAL TRIAL 18435
Phase II study of Copanlisib (BAY 80-6946) in Combination with Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
Condition: Gastrointestinal Tumor
Intervention: BAY 80-6946 (Copanlisib); Copanlisib; Gemzar (gemcitabine); cisplatin; gemcitabine
Open

CLINICAL TRIAL 18322
A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with Hepatocellular Carcinoma
Condition: Gastrointestinal Tumor
Intervention: BLU-554
Open

CLINICAL TRIAL 18837
An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors
Condition: Multiple
Intervention: Dexamethasone; Rovalpituzumab Tesirine
Open

CLINICAL TRIAL 18561
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)
Condition: Multiple
Intervention: Not Applicable; Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 18521
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE)Compound KPT-8602 in Patients with Relapsed/Refractory Cancer Indications
Condition: Multiple
Intervention: Abiraterone acetate; Dexamethasone; KPT-8602; Zytiga (Abiraterone acetate)
Open

CLINICAL TRIAL 18051
A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients with Relapsed/Refractory Metastatic Colorectal Carcinoma
Condition: Gastrointestinal Tumor
Intervention: MGD007
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Patel SP, Kim DW, Bassett RL, Cain S, Washington E, Hwu WJ, Kim KB, Papadopoulos NE, Homsi J, Hwu P, Bedikian AY. A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma. Cancer Immunol Immun. 2017 Jun. Pubmedid: 28612140.
  • Haymaker CL, Kim D, Uemura M, Vence LM, Phillip A, McQuail N, Brown PD, Fernandez I, Hudgens CW, Creasy C, Hwu WJ, Sharma P, Tetzlaff MT, Allison JP, Hwu P, Bernatchez C, Diab A. Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade. Cancer Immunol Res. 2017 Feb;5(2):100-105. Pubmedid: 28062513.
  • Kim DW, Talati C, Kim R. Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy. J Gastrointest Oncol. 2017 Apr;8(2):256-265. Pubmedid: 28480065. Pmcid: PMC5401857.
  • Kim DW, Haydu LE, Joon AY, Bassett RL, Siroy AE, Tetzlaff MT, Routbort MJ, Amaria RN, Wargo JA, McQuade JL, Kemnade J, Hwu P, Woodman SE, Roszik J, Kim KB, Gershenwald JE, Lazar AJ, Davies MA. Clinicopathological features and clinical outcomes associated with TP53 and BRAF(N)(on-)(V)(600) mutations in cutaneous melanoma patients. Cancer. 2017 Apr;123(8):1372-1381. Pubmedid: 27911979. Pmcid: PMC5384865.
  • Kim DW, Byer J, Kothari N, Mahipal A, Chang YD, Kim RD. EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience. Oncology-Basel. 2017 Apr;92(4):190-196. Pubmedid: 28152526.
  • Uemura M, Trinh VA, Haymaker C, Jackson N, Kim DW, Allison JP, Sharma P, Vence L, Bernatchez C, Hwu P, Diab A. Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report. J Hematol Oncol. 2016 Sep;9(1):81. Pubmedid: 27595932. Pmcid: PMC5011857.
  • Patel SP, Kim DW, Lacey CL, Hwu P. GNA11 Mutation in a Patient With Cutaneous Origin Melanoma: A Case Report. Medicine. 2016 Jan;95(4):e2336. Pubmedid: 26825879. Pmcid: PMC5291549.
  • Chattopadhyay C, Kim DW, Gombos DS, Oba J, Qin Y, Williams MD, Esmaeli B, Grimm EA, Wargo JA, Woodman SE, Patel SP. Uveal melanoma: From diagnosis to treatment and the science in between. Cancer. 2016 Aug;122(15):2299-2312. Pubmedid: 26991400. Pmcid: PMC5567680.
  • Kim DW, Barcena E, Mehta UN, Rohlfs ML, Kumar AJ, Penas-Prado M, Kim KB. Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report. BMC Cancer. 2015 May;15:400. Pubmedid: 25962795. Pmcid: PMC4440312.
  • Kim DW, Patel SP. Profile of selumetinib and its potential in the treatment of melanoma. Onco Targets Ther. 2014 Sep;7:1631-1639. Pubmedid: 25278770. Pmcid: PMC4179759.
  • Kim DW, Trinh VA, Hwu WJ. Ipilimumab in the treatment of advanced melanoma - a clinical update. Expert Opin Biol Ther. 2014 Nov;14(11):1709-1718. Pubmedid: 25250971.
  • Zloza A, Kim DW, Broucek J, Schenkel JM, Kaufman HL. High-dose IL-2 induces rapid albumin uptake by endothelial cells through Src-dependent caveolae-mediated endocytosis. J Interferon Cytokine Res. 2014 Nov;34(11):915-919. Pubmedid: 24963699. Pmcid: PMC4217041.
  • Kim DW, Zloza A, Broucek J, Schenkel JM, Ruby C, Samaha G, Kaufman HL. Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells. J Transl Med. 2014 May;12:113. Pubmedid: 24885155. Pmcid: PMC4062649.
  • Kaufman HL, Kim DW, Kim-Schulze S, DeRaffele G, Jagoda MC, Broucek JR, Zloza A. Results of a randomized phase I gene therapy clinical trial of nononcolytic fowlpox viruses encoding T cell costimulatory molecules. Hum Gene Ther. 2014 May;25(5):452-460. Pubmedid: 24484178. Pmcid: PMC4027985.
  • Kim CY, Kim DW, Kim K, Curry J, Torres-Cabala C, Patel S. GNAQ mutation in a patient with metastatic mucosal melanoma. BMC Cancer. 2014 Jul;14:516. Pubmedid: 25030020. Pmcid: PMC4223398.
  • Zloza A, Kim DW, Kim-Schulze S, Jagoda MC, Monsurro V, Marincola FM, Kaufman HL. Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses. J Immunother Cancer. 2014 Jan;2:1. Pubmedid: 24829758. Pmcid: PMC4019911.
  • Kim DW, Krishnamurthy V, Bines SD, Kaufman HL. TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: lessons learned and future development. Hum Vaccin. 2010 Oct;6(10):784-791. Pubmedid: 20975327.
  • Seo SW, Lee D, Minematsu H, Kim AD, Shin M, Cho SK, Kim DW, Yang J, Lee FY. Targeting extracellular signal-regulated kinase (ERK) signaling has therapeutic implications for inflammatory osteolysis. Bone. 2010 Mar;46(3):695-702. Pubmedid: 19895919. Pmcid: PMC2823832.
  • Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol. 2010 Mar;17(3):718-730. Pubmedid: 19915919.
  • Kim HS, Kim-Schulze S, Kim DW, Kaufman HL. Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand. Cancer Res. 2009 Nov;69(21):8516-8525. Pubmedid: 19843856.
  • Kim DW, Kim KO, Shin MJ, Ha JH, Seo SW, Yang J, Lee FY. siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells. Mol Cancer. 2009 May;8:28. Pubmedid: 19445670. Pmcid: PMC2689171.
  • Sabatino M, Kim-Schulze S, Panelli MC, Stroncek D, Wang E, Taback B, Kim DW, Deraffele G, Pos Z, Marincola FM, Kaufman HL. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol. 2009 Jun;27(16):2645-2652. Pubmedid: 19364969. Pmcid: PMC2689845.
  • Kaufman HL, Taback B, Sherman W, Kim DW, Shingler WH, Moroziewicz D, DeRaffele G, Mitcham J, Carroll MW, Harrop R, Naylor S, Kim-Schulze S. Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med. 2009 Jan;7:2. Pubmedid: 19128501. Pmcid: PMC2631474.
  • Kim-Schulze S, Kim HS, Fan Q, Kim DW, Kaufman HL. Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment. Mol Ther. 2009 Feb;17(2):380-388. Pubmedid: 19034262. Pmcid: PMC2835064.
  • Kim-Schulze S, Kim HS, Wainstein A, Kim DW, Yang WC, Moroziewicz D, Mong PY, Bereta M, Taback B, Wang Q, Kaufman HL. Intrarectal vaccination with recombinant vaccinia virus expressing carcinoembronic antigen induces mucosal and systemic immunity and prevents progression of colorectal cancer. J Immunol. 2008 Dec;181(11):8112-8119. Pubmedid: 19018004.
  • Minematsu H, Shin MJ, Celil Aydemir AB, Seo SW, Kim DW, Blaine TA, Macián F, Yang J, Lee FY, Young-In Lee F. Orthopedic implant particle-induced tumor necrosis factor-alpha production in macrophage-monocyte lineage cells is mediated by nuclear factor of activated T cells. Ann Ny Acad Sci. 2007 Nov;1117:143-150. Pubmedid: 18056040.
  • Celil Aydemir AB, Lee S, Won Kim D, Gardner TR, Prince D, Mok Ahn J, Lee FY, Young-In Lee F. Nuclear factor of activated T cell mediates proinflammatory gene expression in response to mechanotransduction. Ann Ny Acad Sci. 2007 Nov;1117:138-142. Pubmedid: 17584983.
  • Kaufman HL, Kim-Schulze S, Manson K, DeRaffele G, Mitcham J, Seo KS, Kim DW, Marshall J. Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. J Transl Med. 2007 Nov;5:60. Pubmedid: 18039393. Pmcid: PMC2217514.
  • Kim DW, Seo SW, Cho SK, Chang SS, Lee HW, Lee SE, Block JA, Hei TK, Lee FY. Targeting of cell survival genes using small interfering RNAs (siRNAs) enhances radiosensitivity of Grade II chondrosarcoma cells. J Orthop Res. 2007 Jun;25(6):820-828. Pubmedid: 17343283.
  • Kim DW, Lee HJ, Karmin JA, Lee SE, Chang SS, Tolchin B, Lin S, Cho SK, Kwon A, Ahn JM, Lee FY. Mechanical loading differentially regulates membrane-bound and soluble RANKL availability in MC3T3-E1 cells. Ann Ny Acad Sci. 2006 Apr;1068:568-572. Pubmedid: 16831954.
  • Lee FY, Kim DW, Karmin JA, Hong D, Chang SS, Fujisawa M, Takayanagi H, Bigliani LU, Blaine TA, Lee HJ. mu-Calpain regulates receptor activator of NF-kappaB ligand (RANKL)-supported osteoclastogenesis via NF-kappaB activation in RAW 264.7 cells. J Biol Chem. 2005 Aug;280(33):29929-29936. Pubmedid: 15955824.